2023-10-10T10:21:26-05:00 2022-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2022-01-01 812076517 INSTITUTE FOR ADVANCED CLINICAL TRIALS FOR CHILDREN INST 3016057571 9200 CORPORATE BLVD 350 ROCKVILLE MD 20850 LAURA LOPEZ CFAO 3016057571 2023-10-10 1 LAURA LOPEZ 999009999 0 RICHARD J LOCASTRO CPA P00288314 3019519090 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z LAURA LOPEZ 9200 CORPORATE BLVD 350 ROCKVILLE MD 20850 3309135 0 X WWW.IACTC.ORG X 2016 DE SEE PART III, LINE 1. 8 8 25 8 0 0 4045844 2354048 1221523 935146 13051 -15128 0 0 5280418 3274066 295869 132174 0 0 4296976 3498361 0 0 256705 1609283 1477335 6202128 5107870 -921710 -1833804 7633622 5456460 540265 258426 7093357 5198034 X TO FUNCTION AS A NON-PROFIT EDUCATIONAL, SCIENTIFIC AND RESEARCH ORGANIZATION TO ENABLE AND ADVANCE PEDIATRIC CLINICAL RESEARCH PRESCRIBED BY REGULATION THROUGH (1) DEVELOPING, ADVANCING, ACCUMULATING AND MAINTAINING SCIENTIFIC (CONTINUED ON SCHEDULE O) KNOWLEDGE REGARDING BEST PRACTICES AND STRATEGIES FOR THE CONDUCT OF PEDIATRIC CLINICAL RESEARCH AND TREATMENT OF CHILDREN THROUGH THE CONDUCT OF PEDIATRIC CLINICAL RESEARCH; (2) EDUCATING ITS MEMBERS AND OTHERS ABOUT THE BEST PRACTICES AND STRATEGIES IN PEDIATRIC RESEARCH AND AIDING THEM IN OBTAINING HIGH-QUALITY DATA USEFUL FOR THE ADVANCEMENT OF SCIENTIFIC KNOWLEDGE; (3) DISSEMINATING INFORMATION AND SCIENTIFIC RESEARCH TO AND FACILITATING COMMUNICATION AMONG RESEARCHERS, CLINICAL RESEARCH SPONSORS, REGULATORS AND OTHER STAKEHOLDERS REGARDING BEST PRACTICES AND STRATEGIES FOR THE CONDUCT OF PEDIATRIC CLINICAL RESEARCH; 0 0 3188290 132174 935146 DURING THIS TIME PERIOD, THE ORGANIZATION MADE APPLICATIONS FOR CONTRIBUTIONS AND MEMBERSHIP FEES. ONE GRANT AS SUBRECIPIENT WAS FUNDED IN SEPTEMBER 2022; AND TWO MEMBERSHIP FEES WERE RECEIVED IN 2022. THROUGHOUT 2022, CLINICAL PROGRAM GUIDANCE SERVICES WERE PERFORMED FOR FIVE MEMBERS AND SIX NON-MEMBERS. THERE WERE MINIMAL ADDITIONAL FINANCIAL CONTRIBUTIONS. THE ORGANIZATION PROVIDES EXPERT GUIDANCE AND INPUT ON PEDIATRIC CLINICAL DEVELOPMENT PLANS AND PEDIATRIC CLINICAL TRIALS WITH THE GOAL OF IMPROVING THE PROCESSES AND ACCELERATING THE DEVELOPMENT OF INNOVATIVE PRODUCTS FOR THE USE IN CHILDREN. ADDITIONALLY, THE ORGANIZATION ALSO CONNECTS QUALIFIED CLINICAL (CONTINUED ON SCHEDULE O) TRIAL SITES IN OUR PEDIATRIC CLINICAL TRIAL SITE NETWORK WITH CLINICAL TRIALS FOR A VARIETY OF BIOPHARMACEUTICAL SPONSORS. THE ORGANIZATION UTILIZES ITS NETWORK OF EXPERTS TO CONVENE WORKING GROUPS TO TACKLE PROBLEMS IN PEDIATRIC CLINICAL DEVELOPMENT COMMON ACROSS A VARIETY OF STAKEHOLDERS, THAT OTHERWISE WOULD NOT BE ADDRESSED IN A PRECOMPETITIVE MANNER. IN 2022, THE ORGANIZATION DEVELOPED, ORGANIZED, AND IMPLEMENTED A SERIES OF MEETINGS CULMINATING IN A 2-WEBINAR SERIES HELD IN 2023 FOCUSED ON ANTI-BACTERIAL DRUG DEVELOPMENT. FACILITATING PEDIATRIC CLINICAL RESEARCH IN ACCORDANCE WITH BEST PRACTICES AND STRATEGIES TO FURTHER SCIENTIFIC KNOWLEDGE; ASSISTING GOVERNMENTAL AGENCIES AND GOVERNMENTAL REGULATORY AUTHORITIES IN CONNECTION WITH MEETING OR FULFILLING THEIR GOALS AND RESPONSIBILITIES RELATED TO PEDIATRIC RESEARCH; AND ENGAGING IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH CORPORATIONS MAY BE ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW. AS AMENDED FROM TIME TO TIME. 3188290 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 33 0 1 25 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 8 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD X LAURA LOPEZ 3016057571 9200 CORPORATE BLVD 350 ROCKVILLE MD 20850 ELIZABETH GAROFALO MD CHAIRWOMAN 3.00 X X 0 0 0 MARTHA BRUMFIELD PHD SECRETARY/TREASURER 3.00 X X 0 0 0 ROBERT WARD MD VICE PRESIDENT 3.00 X X 0 0 0 BARRY BROOKS JD DIRECTOR 3.00 X 0 0 0 JAMES POMFRET DIRECTOR 3.00 X 0 0 0 EDWARD CONNOR MD DIRECTOR 3.00 X 0 0 0 MAX COPPES MD PHD DIRECTOR 3.00 X 0 0 0 JEFF BARRETT PHD DIRECTOR 3.00 X 0 0 0 GARY NOEL MD CHIEF MEDICAL OFFICER 40.00 X 329477 0 10281 ALEX LEBEAUT MD CHIEF EXECUTIVE OFFICER 40.00 X 368735 0 36616 CYNTHIA JACKSON DILIBERTI MD CHIEF OPERATING OFFICER 40.00 X 305998 0 38436 LAURA LOPEZ CHIEF FINANCIAL AND ADMIN. OFFICER 40.00 X 181865 0 24028 COLLIN HOVINGA SVP CLINICAL AND SCIENTIFIC DEV. 40.00 X 210246 0 8323 DAVID MC NEELEY MD SVP, CLINICAL DEV. PED. 40.00 X 208423 0 28688 HOLLY HUNTINGTON HEAD, CLINICAL RESEARCH NETWORK OPS 40.00 X 207829 0 24457 SEON BAICK SR CLINICAL PROJ MGR 40.00 X 131306 0 6419 CALLIE HEATON DIR., CLINICAL PROJECT MGMT 40.00 X 163350 0 8589 ANGELA PRICE DIR., CLINICAL SITE NETWORK - QI 40.00 X 142839 0 15995 FAYNE MOORE SR MANAGER, CLINICAL SITE NETWORK 40.00 X 114735 0 19363 GABRIELA TULLOCH SR MANAGER, CLINICAL SITE NETWORK 40.00 X 130604 0 19488 2495407 0 240683 12 0 1 0 SPARK EXCELLENCE LLC 20600 CAMDEN PATH FARMINGTON MN 55024 QUALITY IMPROVEMENT EDUCATIONAL SERVICES 100734 KERRY WEST CONSULTING 1012 STONEY LANE CROWNSVILLE MD 21032 HR, RECRUITING & CONSULTING SERVICES 100463 2 1250000 977542 126506 2354048 CLINICAL PROGRAM GUIDA 900099 935146 935146 935146 19941 19941 35069 -35069 -35069 -35069 3274066 935146 0 -15128 X 117174 117174 15000 15000 1983402 1243796 658536 81070 1198376 880901 300893 16582 37988 29307 8587 94 88609 62608 24495 1506 189986 127290 56996 5700 31407 14169 17238 119808 54052 65756 844393 485216 232214 126963 88 23 42 23 39100 12769 23682 2649 213920 43605 153473 16842 137351 64857 68310 4184 53169 24642 28207 320 3265 1513 1732 20 6672 6672 28162 11368 16042 752 5107870 3188290 1662875 256705 1699048 1507358 2446162 2459656 2715358 1272132 300791 64483 112113 86644 10646 7285 45102 3361 315048 62826 7633622 5456460 188263 81326 117175 352002 59925 540265 258426 X 4493357 3948034 2600000 1250000 7093357 5198034 7633622 5456460 X -1833804 -61519 X 0 1 X 1 1 1 X 1462528 4916202 5953742 4045844 2354048 18732364 1462528 4916202 5953742 4045844 2354048 18732364 8836092 9896272 29210 79565 49330 13051 19941 191097 400 400 18923861 4382493 0.52300 0.49330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5045 5045 0 5601 2240 3361 3361 LEASE LIABILITY 59925 59925 X 3309135 0 3309135 -35069 -35069 3274066 5107870 0 5107870 0 5107870 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2022, I-ACT HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF FIXED ASSETS 1 SOUTH AMERICA 0 0 GRANTS 7500 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS 7500 0 0 0 0 0 0 15000 0 15000 SOUTH AMERICA PROGRAM SUPPORT 7500 WIRE 0 CENTRAL AMERICA AND THE CARIBBEAN PROGRAM SUPPORT 7500 WIRE 0 0 2 0 0 0 0 0 0 PART I, LINE 2: UTILIZE UNIFORM GUIDANCE, GAAP PROCEDURES AND CONTRACTS. PART III ACCOUNTING METHOD: 1 CHILDREN'S NATIONAL MEDICAL CENTER 111 MICHIGAN AVE NW WASHINGTON DC 20010 521640403 501(C)(3) 19143 0 RESEARCH CHILDREN'S NATIONAL MEDICAL CENTER CINCINNATI 3333 BURNETT AVENUE CINCINNATI OH 45229 310537130 501(C)(3) 36792 0 RESEARCH CRITICAL PATH INSTITUTE 1730 E RIVER ROAD 200 TUCSON AZ 85718 201991334 501(C)(3) 13884 0 RESEARCH RUTGERS BIOMEDICAL AND HEALTH SERVICES 33 KNIGHTSBRIDGE ROAD PISCATAWAY NJ 08854 462354111 GOVERNMENT 7500 0 PROGRAM SUPPORT UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION PO BOX 405803 ATLANTA GA 303845803 590624458 501(C)(3) 7500 0 PROGRAM SUPPORT ARIZONA ALLERGY & IMMUNOLOGY RESEARCH LLC 4915 E BASELINE RD STE 110-112 GILBERT AZ 85234 463255646 N/A 7500 0 PROGRAM SUPPORT GILLETTE CHILDREN'S SPECIALTY HEALTHCARE 200 UNIVERSITY AVENUE EAST SAINT PAUL MN 55101 363379150 501(C)(3) 7500 0 PROGRAM SUPPORT THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 972 BUSH HOLLOW ROAD 5TH FLOOR WESTBURY NY 11590 112673595 501(C)(3) 7500 0 PROGRAM SUPPORT GEORGETOWN UNIVERSITY 37TH AND O STREETS NW WASHINGTON DC 20057 530196603 501 (C)(3) 7500 0 PROGRAM SUPPORT 8 1 PART I, LINE 2: I-ACT FOR CHILDREN MAINTAINS A PRE-QUALIFIED PEDIATRIC SITE NETWORK. I-ACT'S INFRASTRUCTURE SUPPORTS A VARIETY OF PROGRAMS FOR THE CLINICAL TRIAL SITES. THESE PROGRAMS INCLUDE QUARTERLY INFORMATIONAL CALLS, SITE STAFF EDUCATIONAL FORUMS (3 OCCURRED IN 2022), SITE STAFF EDUCATIONAL GRANT PROGRAMS, AND A YEARLY SITE STAFF AWARD. I-ACT FOR CHILDREN ALSO ASSISTS OUR SITES IN ENROLLING IN THE SHARED INVESTIGATOR PLATFORM (SIP), WHICH IS REQUIRED BY SOME SPONSORS TO BE CHOSEN AS INVESTIGATIVE SITES. OUR SITE NETWORK STAFF ALSO PERFORMS OUTREACH CALLS AND ON-SITE VISITS TO ASSESS THE SITES ONGOING QUALITY, STAFFING, PROCESSES AND MITIGATES ANY ISSUES WHICH MAY BE DISCOVERED. IN 2022, I-ACT FOR CHILDREN'S SITE NETWORK INCLUDED 81 SITES LOCATED IN THE UNITED STATES, AUSTRALIA, COLUMBIA, PANAMA, SOUTH AFRICA AND SAUDI ARABIA. AFTER THE INITIAL QUALIFICATION VISIT, SITES WERE PAID $7,500 FOR START-UP COSTS INCURRED AS PART OF THE PROCESS TO BECOME AN I-ACT SITE. SIX SUCH PAYMENTS WERE MADE IN 2022. FUNDING PROVIDED TO SUPPORT THE SITE'S PERSONNEL TIME AND EFFORT FOR SITE STARTUP ACTIVITIES, WHICH INCLUDE CONTRACT REVIEW AND EXECUTION, IRB RELATED WORK, STAFFING MODEL FOR I-ACT PROJECT WORK, DOCUMENT COMPLETION, AND INSTITUTIONAL EDUCATION ABOUT I-ACT AND ITS MISSION. IN ADDITION, THESE FUNDS WILL SUPPORT TIME AND EFFORT SPENT ON THE REVIEW OF PROJECT WORK SENT TO THE SITE FOR POTENTIAL SITE PARTICIPATION. X X X 1 0 0 0 0 0 0 1 0 ALEX LEBEAUT MD CHIEF EXECUTIVE OFFICER 368735 0 0 0 0 0 14659 0 21957 0 405351 0 0 0 CYNTHIA JACKSON DILIBERTI MD CHIEF OPERATING OFFICER 305998 0 0 0 0 0 12728 0 25708 0 344434 0 0 0 GARY NOEL MD CHIEF MEDICAL OFFICER 329477 0 0 0 0 0 8551 0 1730 0 339758 0 0 0 DAVID MC NEELEY MD SVP, CLINICAL DEV. PED. 186500 0 0 0 21923 0 7817 0 20871 0 237111 0 0 0 HOLLY HUNTINGTON HEAD, CLINICAL RESEARCH NETWORK OPS 205829 0 2000 0 0 0 4375 0 20082 0 232286 0 0 0 COLLIN HOVINGA SVP CLINICAL AND SCIENTIFIC DEV. 175625 0 0 0 34621 0 7055 0 1268 0 218569 0 0 0 LAURA LOPEZ CHIEF FINANCIAL AND ADMIN. OFFICER 176865 0 5000 0 0 0 7672 0 16356 0 205893 0 0 0 CALLIE HEATON DIR., CLINICAL PROJECT MGMT 161850 0 1500 0 0 0 7055 0 1534 0 171939 0 0 0 ANGELA PRICE DIR., CLINICAL SITE NETWORK - QI 140839 0 2000 0 0 0 4362 0 11633 0 158834 0 0 0 GABRIELA TULLOCH SR MANAGER, CLINICAL SITE NETWORK 130604 0 0 0 0 0 4631 0 14857 0 150092 0 0 0 PART I, LINE 4A COLLIN HOVINGA, SVP CLINICAL AND SCIENTIFIC DEV. RECEIVED SEVERANCE OF $34,621. DAVID MCNEELEY, SVP CLINICAL DEV. PEDIATRICS RECEIVED SEVERANCE OF $21,923. PART I, LINE 7 THE FOLLOWING INDIVIDUALS LISTED IN FORM 990, PART VII, SECTION A, LINE 1A RECEIVED BONUS PAYMENTS IN 2022: HOLLY HUNTINGTON $2,000 LAURA LOPEZ $5,000 CALLIE HEATON $1,500 ANGELA PRICE $2,000 SEON BAICK $1,500 FORM 990, PART III, LINE 1 CONTINUATION: (4) FACILITATING AND CONDUCTING PEDIATRIC CLINICAL RESEARCH IN ACCORDANCE WITH BEST PRACTICES IN ACCORDANCE WITH BEST PRACTICES AND STRATEGIES TO FURTHER SCIENTIFIC KNOWLEDGE; (5) ASSISTING GOVERNMENTAL AGENCIES AND GOVERNMENTAL REGULATORY AUTHORITIES IN CONNECTION WITH MEETING OR FULFILLING THEIR GOALS AND RESPONSIBILITIES RELATED TO PEDIATRIC RESEARCH; AND (6) ENGAGING IN ANY LAWFUL ACT OR ACTIVITY FOR WHICH CORPORATIONS MAY BE ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW. AS AMENDED FROM TIME TO TIME. ALSO, TO ENGAGE IN ANY LAWFUL ACT OR ACTIVITY PERMITTED FOR ORGANIZATIONS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS THREE CLASSES OF MEMBERS: (1) FOUNDING MEMBERS, CONSISTING OF CRITICAL PATH INSITUTE, CLINICAL RESEARCH ALLIANCE, LLC AND ROBERT M. WARD, MD; (2) SUSTAINING MEMBERS, CONSISTING OF ORGANIZATIONS THAT PROVIDE SUBSTANTIAL UNRESTRICTED FUNDS AS DUES TO THE CORPORATION OVER AN INITIAL MEMBERSHIP TERM OF FIVE YEARS; AND (3) GENERAL MEMBERS, CONSISTING OF THOSE SUPPORTING THE PURPOSE AND ACTIVITIES OF THE CORPORATION OVER A ONE-YEAR TERM OF MEMBERSHIP. FORM 990, PART VI, SECTION A, LINE 7A FOUNDING AND SUSTAINING MEMBERS HAVE THE RIGHT TO VOTE ON BOARD OF DIRECTORS NOMINEES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE AUDIT AND COMPENSATION COMMITTEE AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. FORM 990, PART VI, SECTION B, LINE 12C TO ENSURE THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH CHARITABLE PURPOSES AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE TAX-EXEMPT STATUS, PERIODIC REVIEWS SHALL BE CONDUCTED. THE PERIODIC REVIEWS SHALL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS: (1) WHETHER COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND THE RESULT OF ARM'S LENGTH BARGAINING, AND (2) WHETHER PARTNERSHIPS, JOINT VENTURES AND ARRANGEMENTS WITH MANAGEMENT ORGANIZATIONS CONFORM TO THE CORPORATION'S WRITTEN POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE INVESTMENT OR PAYMENTS FOR GOODS AND SERVICES, FURTHER CHARITABLE PURPOSES AND DO NOT RESULT IN INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR IN AN EXCESS BENEFIT TRANSACTION. WHEN CONDUCTING THE PERIODIC REVIEWS, THE ORGANIZATION MAY, BUT NEED NOT, USE OUTSIDE ADVISORS. IF OUTSIDE ADVISORS ARE USED, THEIR USE SHALL NOT RELIEVE THE GOVERNING BOARD OF ITS RESPONSIBILITY FOR ENSURING PERIODIC REVIEWS ARE CONDUCTED. FORM 990, PART VI, SECTION B, LINE 15 THE TOP MANAGEMENT OFFICIAL, CEO, HAS COMPENSATION REVIEW BY AN INDEPENDENT PERSON (HR CONSULTANT AND AUDIT AND COMPENSATION COMMITTEE CHAIR, OR BOARD OF DIRECTORS APPOINTEE), COMPARABILITY DATA FROM BENCHMARKING AND DELIBERATION AND DECISION IS REFLECTED IN THE BOARD MEETING MINUTES. THE APPROVED PAY RATE UPON HIRE IS VALIDATED BY A SIGNED OFFER LETTER BY THE BOARD CHAIRPERSON FOR THE CEO. FOR THE CMO AND COO POSITIONS, THE CEO, OR THE BOARD OF DIRECTORS CHAIRPERSON, WILL EVALUATE THE BENCHMARKING AND SIGN THE OFFER LETTER FOR THE APPROVED PAY RATE. FORM 990, PART VI, SECTION C, LINE 19 THE ARTICLES OF INCORPORATION, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G COMMUNICATION & PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 37,099. MANAGEMENT AND GENERAL EXPENSES 17,755. FUNDRAISING EXPENSES 9,708. TOTAL EXPENSES 64,562. PAYROLL & BENEFIT SERVICES: PROGRAM SERVICE EXPENSES 5,202. MANAGEMENT AND GENERAL EXPENSES 2,489. FUNDRAISING EXPENSES 1,361. TOTAL EXPENSES 9,052. CONTRACTORS: PROGRAM SERVICE EXPENSES 138. MANAGEMENT AND GENERAL EXPENSES 66. FUNDRAISING EXPENSES 36. TOTAL EXPENSES 240. CONSULTANT - PHYSICIAN: PROGRAM SERVICE EXPENSES 3,563. MANAGEMENT AND GENERAL EXPENSES 1,705. FUNDRAISING EXPENSES 932. TOTAL EXPENSES 6,200. OTHER CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 187,574. MANAGEMENT AND GENERAL EXPENSES 89,768. FUNDRAISING EXPENSES 49,081. TOTAL EXPENSES 326,423. CONTRACTOR - PHYSICIAN: PROGRAM SERVICE EXPENSES 16,609. MANAGEMENT AND GENERAL EXPENSES 7,948. FUNDRAISING EXPENSES 4,346. TOTAL EXPENSES 28,903. RECRUITMENT: PROGRAM SERVICE EXPENSES 731. MANAGEMENT AND GENERAL EXPENSES 350. FUNDRAISING EXPENSES 191. TOTAL EXPENSES 1,272. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 230,924. MANAGEMENT AND GENERAL EXPENSES 110,517. FUNDRAISING EXPENSES 60,425. TOTAL EXPENSES 401,866. CONSULTANT - SCIENTIST: PROGRAM SERVICE EXPENSES 3,376. MANAGEMENT AND GENERAL EXPENSES 1,616. FUNDRAISING EXPENSES 883. TOTAL EXPENSES 5,875. FORM 990, PART XI, LINE 9: EARLY LEASE TERMINATION FEE -89,408. WRITE OFF OF OPERATING LEASE 27,889.